Game of Omes: ribosome profiling expands the MHC-I immunopeptidome.


Journal

Current opinion in immunology
ISSN: 1879-0372
Titre abrégé: Curr Opin Immunol
Pays: England
ID NLM: 8900118

Informations de publication

Date de publication:
08 2023
Historique:
received: 12 03 2023
revised: 25 04 2023
accepted: 26 04 2023
pmc-release: 01 08 2024
medline: 7 8 2023
pubmed: 30 5 2023
entrez: 29 5 2023
Statut: ppublish

Résumé

Peptide ligands presented by cell-surface MHC class-I molecules enable T cells to eradicate intracellular pathogens and cancers. The presented peptide repertoire, the class-I immunopeptidome, is generated from each cell's translatome in a highly biased manner to avoid overrepresenting highly abundant translation products. The immunopeptidome can only be defined by mass spectrometry (MS). Here, we review recent advances in immunopeptidomics, focusing on using ribosome profiling as the optimal MS database to optimize the false- and failed-discovery rates and relate these findings to the contribution of defective ribosomal products and cellular quality control mechanisms to MHC class-I antigen processing and presentation.

Identifiants

pubmed: 37247567
pii: S0952-7915(23)00061-4
doi: 10.1016/j.coi.2023.102342
pmc: PMC10524008
mid: NIHMS1899185
pii:
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Peptides 0

Types de publication

Journal Article Review Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

102342

Subventions

Organisme : Intramural NIH HHS
ID : Z99 AI999999
Pays : United States

Informations de copyright

Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors of the submitted paper, namely, Jonathan W. Yewdell and Jaroslav Holly, declare no conflict of interest.

Références

Nature. 2021 Feb;590(7845):332-337
pubmed: 33328638
Genome Biol. 2021 Aug 13;22(1):223
pubmed: 34389041
Immunology. 2023 Mar;168(3):420-431
pubmed: 36111495
Mol Cell Proteomics. 2021;20:100099
pubmed: 34022431
Curr Opin Immunol. 2020 Jun;64:130-136
pubmed: 32615334
FASEB J. 2019 Oct;33(10):11458-11468
pubmed: 31343935
Nat Biotechnol. 2020 Feb;38(2):199-209
pubmed: 31844290
J Exp Med. 1992 Jan 1;175(1):163-8
pubmed: 1309852
Mol Biol Cell. 2021 Dec 1;32(22):ar38
pubmed: 34586879
Immunogenetics. 1989;29(2):75-9
pubmed: 2783681
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4099-4108
pubmed: 32047030
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):
pubmed: 33568529
Nat Immunol. 2016 Jan;17(1):104-12
pubmed: 26551880
Nature. 2022 Mar;603(7902):721-727
pubmed: 35264796
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19399-19407
pubmed: 32719124
Mol Cell. 2021 Nov 18;81(22):4709-4721.e9
pubmed: 34562372
J Cell Biol. 2012 Apr 2;197(1):45-57
pubmed: 22472439
Cancers (Basel). 2021 Dec 08;13(24):
pubmed: 34944805
Nucleic Acids Res. 2021 Aug 20;49(14):8261-8276
pubmed: 34232997
Proc Natl Acad Sci U S A. 2012 May 1;109(18):7025-30
pubmed: 22509014
Nature. 2022 Jul;607(7917):149-155
pubmed: 35705813
Proc Natl Acad Sci U S A. 2023 Feb 14;120(7):e2208509120
pubmed: 36745791
Immunity. 2004 Jul;21(1):81-93
pubmed: 15345222
Mol Cell Proteomics. 2023 Apr;22(4):100506
pubmed: 36796642
Cell Rep. 2022 Aug 16;40(7):111241
pubmed: 35977509
Cell Rep. 2021 Mar 9;34(10):108815
pubmed: 33691108
Nat Commun. 2019 Jun 28;10(1):2846
pubmed: 31253788
J Immunol. 1996 Sep 1;157(5):1823-6
pubmed: 8757297
Mol Cell. 2022 Jul 21;82(14):2557-2570.e7
pubmed: 35594857
J Exp Med. 1997 Aug 18;186(4):479-87
pubmed: 9254646
Cell. 2021 Jul 22;184(15):3962-3980.e17
pubmed: 34171305
Nat Biotechnol. 2022 Feb;40(2):209-217
pubmed: 34663921
Nat Commun. 2023 Feb 25;14(1):1078
pubmed: 36841868
Cancer Immunol Res. 2020 Aug;8(8):1018-1026
pubmed: 32561536
Cell Mol Life Sci. 2010 Mar;67(5):677-700
pubmed: 19859661
J Immunol. 2010 Dec 1;185(11):6728-33
pubmed: 21048111
J Exp Med. 1996 Feb 1;183(2):527-34
pubmed: 8627164
Mol Cell. 2022 Oct 20;82(20):3840-3855.e8
pubmed: 36270248
Sci Transl Med. 2022 Aug 31;14(660):eabo6135
pubmed: 36044599
Int J Mol Sci. 2021 Dec 28;23(1):
pubmed: 35008707
J Exp Med. 2006 May 15;203(5):1259-71
pubmed: 16636135
Nat Rev Immunol. 2020 Oct;20(10):644
pubmed: 32873889
Cold Spring Harb Perspect Biol. 2019 May 1;11(5):
pubmed: 30037969
Nat Commun. 2020 Mar 10;11(1):1293
pubmed: 32157095

Auteurs

Jaroslav Holly (J)

Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Jonathan W Yewdell (JW)

Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: jyewdell@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH